DGIdb - PDGFRB Gene Record

PDGFRB 5159 Druggable GenomeClinically Actionable

Alternate Names:

5159
PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA
PDGFRB
CD140B
IBGC4
IMF1
JTK12
KOGS
PDGFR
PDGFR-1
PDGFR1
PENTT
173410
8804
ENSG00000113721
OTTHUMG00000130053
P09619
PGFRB_HUMAN
CD140 antigen-like family member B
Platelet-derived growth factor receptor beta
Beta platelet-derived growth factor receptor
Beta-type platelet-derived growth factor receptor
PDGFR-beta
PDGF-R-beta
CD_antigen=CD140b
Platelet-derived growth factor receptor 1
1804
NP_002600
NM_002609
platelet-derived growth factor receptor, beta polypeptide
BETA PLATELET-DERIVED GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (PDGF-R-BETA) (CD140B ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P09619]
BE0000205
4176
PA33148
T59102

Gene Info:

Target Subclass	KInase
Target Main Class	Receptors
Transmembrane Helix Count	1
Target Subclass	PDGFR
GuideToPharmacology Gene Category Name	Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family
GuideToPharmacology Gene Category ID	322
GuideToPharmacology Gene Type	catalytic_receptor
Interpro Acc	IPR001245
Interpro Short Name	Ser-Thr/Tyr_kinase_cat_dom
Uniprot Evidence	1: Evidence at protein level
Human Readable Name	KINASE
Interpro Name	Serine-threonine/tyrosine-protein kinase catalytic domain
Uniprot Status	Swiss-Prot
Human Readable Name	DRUGGABLE GENOME
Interpro Type	Domain
Human Readable Name	TYROSINE KINASE
Source Reported Gene Name	PDGFRB
Target Class	Receptors
Target Subclass	EC:2.7.10.1
Gene Biotype	PROTEIN_CODING

(23 More Sources)

Gene Categories: Category Details

PROTEIN PHOSPHATASE
CELL SURFACE
TUMOR SUPPRESSOR
KINASE
SERINE THREONINE KINASE
TYROSINE KINASE
G PROTEIN COUPLED RECEPTOR
PHOSPHOLIPASE
DRUGGABLE GENOME
LIPID KINASE
CLINICALLY ACTIONABLE

Publications:

Sonpavde et al., 2007, Pazopanib: a novel multitargeted tyrosine kinase inhibitor., Curr Oncol Rep
Unnithan et al., 2007, The role of targeted therapy in metastatic renal cell carcinoma., ScientificWorldJournal
Gollob, 2005, Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma., Clin Genitourin Cancer
Guida et al., 2007, Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants., Clin. Cancer Res.
Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics
David et al., 2007, Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders., Blood
Sakurai Y et al., 2020, B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review., J Pediatr Hematol Oncol
Lengline E et al., 2013, Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion., Haematologica
Weston et al., 2013, Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia., J. Clin. Oncol.
Jones et al., 2005, The development and application of imatinib., Expert Opin Drug Saf
Modi et al., 2005, A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer., Breast Cancer Res. Treat.
Johnson et al., 2005, Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells., J. Cell. Physiol.
Basciani et al., 2005, Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity., Cancer Res.
Chen et al., 2006, The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression., Cancer Lett.
Chen et al., 2006, Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib)., Mol. Pharmacol.
Zhang et al., 2006, New assignments for multitasking signal transduction inhibitors., Mol. Pharmacol.
Lindauer et al., 2010, Dasatinib., Recent Results Cancer Res.
Xiao W et al., 2018, A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure., Onco Targets Ther
Pietras et al., 2005, A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer., J. Clin. Oncol.
Barattè et al., 2004, Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction., J Chromatogr A
Abrams et al., 2003, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer., Mol. Cancer Ther.
Mendel et al., 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship., Clin. Cancer Res.
Quek R et al., 2009, Gastrointestinal stromal tumor: a clinical overview., Hematol Oncol Clin North Am
Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet
Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
Papanas et al., 2008, Becaplermin gel in the treatment of diabetic neuropathic foot ulcers., Clin Interv Aging
Huang et al., 2010, Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant., J. Med. Chem.
Millward MJ et al., 2006, The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study., Br J Cancer
Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.
Choi BK et al., 2013, Sponge-derived acetylenic alcohols, petrosiols, inhibit proliferation and migration of platelet-derived growth factor (PDGF)-induced vascular smooth muscle cells., Bioorg Med Chem
Hoshiya M et al., 1998, Trapidil inhibits platelet-derived growth factor-stimulated mitogen-activated protein kinase cascade., Hypertension
Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect
Nemunaitis J et al., 2020, Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib., Future Oncol
Cannarile MA et al., 2017, Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy., J Immunother Cancer

PAZOPANIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Publications:

Sonpavde et al., 2007, Pazopanib: a novel multitargeted tyrosine kinase inhibitor., Curr Oncol Rep

NINTEDANIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Publications:

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

BECAPLERMIN PDGFRB

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor agonist

Direct Interaction yes

Trial Name becaplermin,Regranex

Publications:

Papanas et al., 2008, Becaplermin gel in the treatment of diabetic neuropathic foot ulcers., Clin Interv Aging
QUIZARTINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

Publications:
CRENOLANIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

Publications:
CEDIRANIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Publications:
CM-082 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

Publications:
IMATINIB MESYLATE PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

Publications:
ILORASERTIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction Measuring inhibition of kinase activity in a biochemical assay.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Publications:
MASITINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name masitinib, AB1010

Novel drug target Established target

Direct Interaction yes

Publications:
NINTEDANIB ESYLATE PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Publications:
TAK-593 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Publications:
MK-2461 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:
TELATINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name telatinib

Notes

Publications:
DEBIO-1347 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Publications:
MOTESANIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name motesanib diphosphate, AMG 706

Publications:
SU-014813 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Specific Action of the Ligand Inhibition

Publications:
ENMD-981693 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Publications:
TG100-801 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Publications:
SORAFENIB TOSYLATE PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Publications:
DOVITINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name dovitinib, TKI-258, CHIR-258

Novel drug target Established target

Specific Action of the Ligand Inhibition

Publications:
RG-1530 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Publications:
LUCITANIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Publications:
TANDUTINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction? False

Publications:
XL-999 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Publications:
VATALANIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:
REGORAFENIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Notes

Publications:
XL-820 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Publications:
FAMITINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Specific Action of the Ligand Inhibition

Publications:
SEMAXANIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Publications:
LINIFANIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:
SUNITINIB MALATE PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Publications:
chembl:CHEMBL406375 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:
PD-0166285 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

Publications:
X-82 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Publications:
ORANTINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

Publications:
AXITINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name axitinib, AG-013736

Novel drug target Established target

Publications:
JI-101 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

Publications:
FLUMATINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:
chembl:CHEMBL1908396 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:
CDP-860 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

Publications:
PUQUITINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

Publications:
HENATINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:
FORETINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Publications:
PAZOPANIB HYDROCHLORIDE PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Publications:
CEP-2563 PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

Publications:
ANLOTINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

Publications:
TAFETINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction In a radiometric biochemical protein kinase assay.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Publications:

SORAFENIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

antagonist (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Publications:

Unnithan et al., 2007, The role of targeted therapy in metastatic renal cell carcinoma., ScientificWorldJournal

Gollob, 2005, Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma., Clin Genitourin Cancer

Guida et al., 2007, Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants., Clin. Cancer Res.

IMATINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

antagonist (inhibitory)

Interaction Info:

Drug family BCR-ABL inhibitor 1st gen&KIT inhibitor

Alteration PDGFRB__COL1A1

Trial Name imatinib mesylate, STI 571,Gleevec, Glivec

Publications:

David et al., 2007, Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders., Blood

Sakurai Y et al., 2020, B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review., J Pediatr Hematol Oncol

Lengline E et al., 2013, Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion., Haematologica

DASATINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Trial Name dasatinib, BMS-354825,Sprycel

Publications:

Chen et al., 2006, Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib)., Mol. Pharmacol.

Zhang et al., 2006, New assignments for multitasking signal transduction inhibitors., Mol. Pharmacol.

Lindauer et al., 2010, Dasatinib., Recent Results Cancer Res.

SUNITINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Publications:

Xiao W et al., 2018, A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure., Onco Targets Ther

Gollob, 2005, Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma., Clin Genitourin Cancer

Pietras et al., 2005, A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer., J. Clin. Oncol.

MIDOSTAURIN PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Publications:

Millward MJ et al., 2006, The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study., Br J Cancer
HESPERADIN PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.
TRAPIDIL PDGFRB

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Hoshiya M et al., 1998, Trapidil inhibits platelet-derived growth factor-stimulated mitogen-activated protein kinase cascade., Hypertension
FOSTAMATINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect
RIPRETINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Nemunaitis J et al., 2020, Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib., Future Oncol
PEXIDARTINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Cannarile MA et al., 2017, Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy., J Immunother Cancer
NILOTINIB PDGFRB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:
ERDAFITINIB PDGFRB

Interaction Types & Directionality:

substrate

Interaction Info:

Publications:
POLAPREZINC PDGFRB

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Publications:
PEGPLERANIB SODIUM PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name E-10030

Novel drug target Established target

Publications:
LENVATINIB PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name E7080

Novel drug target Established target

Publications:
AMUVATINIB PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name MP-470

Novel drug target Established target

Publications:

PONATINIB PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Huang et al., 2010, Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant., J. Med. Chem.

PETROSIOL A PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Choi BK et al., 2013, Sponge-derived acetylenic alcohols, petrosiols, inhibit proliferation and migration of platelet-derived growth factor (PDGF)-induced vascular smooth muscle cells., Bioorg Med Chem

SOTRASTAURIN PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL574059 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
AZD-1152-HQPA PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
OSI-632 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL606964 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
BARASERTIB PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL106772 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL543669 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL578006 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL546797 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
CENISERTIB PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
SNS-314 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
ROMIPLOSTIM PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL327127 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL230686 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
VANDETANIB PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL406845 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL120077 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL386051 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
TOZASERTIB PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
DORAMAPIMOD PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
SU-11652 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL401930 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
AST-487 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
R-406 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL573820 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
RABEPRAZOLE SODIUM PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
PF-00562271 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
TAE-684 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
chembl:CHEMBL66643 PDGFRB

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Ensembl: ENSG00000113721
- Version: 101_38
Alternate Names:

PDGFRB Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TEND: P09619
- Version: 01-August-2011
Alternate Names:

ENSG00000113721 Ensembl Gene Id

PDGFRB Gene Symbol

PGFRB_HUMAN Uniprot Id

Gene Info:

Target Subclass KInase

Target Main Class Receptors

Transmembrane Helix Count 1

Publications:

GuideToPharmacologyGenes: 1804

Version: 4-March-2015

Alternate Names:

platelet-derived growth factor receptor, beta polypeptide HUGO Gene Name

8804 HUGO Gene ID

PDGFRB Gene Symbol

Gene Info:

GuideToPharmacology Gene Category Name Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family

GuideToPharmacology Gene Category ID 322

GuideToPharmacology Gene Type catalytic_receptor

Gene Categories:

KINASE, TYROSINE KINASE

Publications:

HopkinsGroom: P09619
- Version: 11-September-2012
Alternate Names:

PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA Uniprot Protein Name

P09619 Uniprot Accession

5159 Entrez Gene Id

Gene Info:

Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom

Uniprot Evidence 1: Evidence at protein level

Human Readable Name KINASE

Gene Categories:

KINASE, DRUGGABLE GENOME

Publications:

RussLampel: ENSG00000113721

Version: 26-July-2011

Alternate Names:

ENSG00000113721 Ensembl Gene Id

BETA PLATELET-DERIVED GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (PDGF-R-BETA) (CD140B ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P09619] Description

PDGFRB Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

TdgClinicalTrial: P09619
- Version: January-2014
Alternate Names:

PDGFRB Gene Symbol

Gene Info:

Target Class Receptors

Target Subclass EC:2.7.10.1

Publications:

PharmGKB: PDGFRB

Version: 18-August-2020

Alternate Names:

PA33148 PharmGKB ID

Gene Info:

Publications:

Mendel et al., 2003, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship., Clin. Cancer Res.

Quek R et al., 2009, Gastrointestinal stromal tumor: a clinical overview., Hematol Oncol Clin North Am

Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics

DrugBank: BE0000205

Version: 5.1.7

Alternate Names:

PDGFRB DrugBank Gene Name

P09619 UniProt Accession

5159 Entrez Gene Id

Gene Info:

Publications:

Papanas et al., 2008, Becaplermin gel in the treatment of diabetic neuropathic foot ulcers., Clin Interv Aging

Gollob, 2005, Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma., Clin Genitourin Cancer

Unnithan et al., 2007, The role of targeted therapy in metastatic renal cell carcinoma., ScientificWorldJournal

DTC: PDGFRB

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.

Huang et al., 2010, Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant., J. Med. Chem.

Choi BK et al., 2013, Sponge-derived acetylenic alcohols, petrosiols, inhibit proliferation and migration of platelet-derived growth factor (PDGF)-induced vascular smooth muscle cells., Bioorg Med Chem

HingoraniCasas: ENSG00000113721
- Version: 31-May-2017
Alternate Names:

ENSG00000113721 Gene Symbol

PDGFRB Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
TALC: PDGFRB
- Version: 12-May-2016
Alternate Names:

PDGFRB Gene Symbol

Gene Info:

Publications:
MyCancerGenome: PDGFRB
- Version: 20-Jun-2017
Alternate Names:

5159 Entrez Gene Id

PDGFRB MyCancerGenome Gene Symbol

PDGFR-beta MyCancerGenome Reported Gene Name

Gene Info:

Publications:
ChemblInteractions: PDGFR
- Version: chembl_23
Alternate Names:

PDGFR1 GENE_SYMBOL

PDGFRB GENE_SYMBOL

Platelet-derived growth factor receptor beta UNIPROT

Gene Info:

Publications:
GuideToPharmacologyInteractions: ENSG00000113721
- Version: 20-July-2020
Alternate Names:

platelet derived growth factor receptor beta GuideToPharmacology Name

P09619 UniProtKB ID

Gene Info:

Publications:
OncoKB: PDGFRB
- Version: 23-July-2020
Alternate Names:

5159 OncoKB Entrez Id

PDGFR1 OncoKB Gene Synonym

KOGS OncoKB Gene Synonym

Gene Info:

Publications:
TTD: Platelet-derived growth factor receptor beta
- Version: 2020.06.01
Alternate Names:

PDGFRB TTD Gene Abbreviation

T59102 TTD Target ID

Gene Info:

Publications:
Pharos: PDGFRB
- Version: 03-September-2020
Alternate Names:

Platelet-derived growth factor receptor beta Gene Name

P09619 UniProt ID

Gene Info:

Gene Categories:

KINASE

Publications:
GO: PDGFRB
- Version: 05-September-2020
Alternate Names:

PDGFR GO Gene Synonym

PDGFR1 GO Gene Synonym

Gene Info:

Gene Categories:

CELL SURFACE, TYROSINE KINASE

Publications:
Tempus: PDGFRB
- Version: 11-November-2018
Alternate Names:

PDGFRB Gene Symbol

Gene Info:

Publications:
dGene: PDGFRB
- Version: 27-Jun-2013
Alternate Names:

5159 Gene ID

CD140B dGene Synonym

JTK12 dGene Synonym

Gene Info:

Gene Categories:

KINASE, TYROSINE KINASE

Publications:
ClearityFoundationClinicalTrial: PDGFRB
- Version: 15-June-2013
Alternate Names:

Gene Info:

Publications:
MskImpact: PDGFRB
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
MyCancerGenomeClinicalTrial: PDGFRB
- Version: 30-February-2014
Alternate Names:

Gene Info:

Publications:
FoundationOneGenes: PDGFRB
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: PDGFRB
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FDA: PDGFRB
- Version: 04-September-2020
Alternate Names:

Gene Info:

Publications:
Oncomine: PDGFRB
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Notes
Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

Notes
Trial Name	BIBF-1120,Vargatef
Novel drug target	Established target

Mechanism of Interaction	Platelet-derived growth factor receptor agonist
Direct Interaction	yes
Trial Name	becaplermin,Regranex

Details of the Assay for Interaction	Measuring inhibition of kinase activity in a biochemical assay.
Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

Trial Name	masitinib, AB1010
Novel drug target	Established target
Direct Interaction	yes

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Trial Name	dovitinib, TKI-258, CHIR-258
Novel drug target	Established target
Specific Action of the Ligand	Inhibition

Notes
Trial Name	axitinib, AG-013736
Novel drug target	Established target

Details of the Assay for Interaction	In a radiometric biochemical protein kinase assay.
Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

Drug family	BCR-ABL inhibitor 1st gen&KIT inhibitor
Alteration	PDGFRB__COL1A1
Trial Name	imatinib mesylate, STI 571,Gleevec, Glivec

ENSG00000113721	Ensembl Gene Id
PDGFRB	Gene Symbol
PGFRB_HUMAN	Uniprot Id

platelet-derived growth factor receptor, beta polypeptide	HUGO Gene Name
8804	HUGO Gene ID
PDGFRB	Gene Symbol

PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA	Uniprot Protein Name
P09619	Uniprot Accession
5159	Entrez Gene Id

PDGFRB	DrugBank Gene Name
P09619	UniProt Accession
5159	Entrez Gene Id

PDGFR1	GENE_SYMBOL
PDGFRB	GENE_SYMBOL
Platelet-derived growth factor receptor beta	UNIPROT

platelet derived growth factor receptor beta	GuideToPharmacology Name
P09619	UniProtKB ID

5159	OncoKB Entrez Id
PDGFR1	OncoKB Gene Synonym
KOGS	OncoKB Gene Synonym

Platelet-derived growth factor receptor beta	Gene Name
P09619	UniProt ID

PDGFRB Gene Record

PDGFRB 5159 Druggable GenomeClinically Actionable

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Specific Action of the Ligand Inhibition Endogenous Drug? False

Publications: Sonpavde et al., 2007, Pazopanib: a novel multitargeted tyrosine kinase inhibitor., Curr Oncol Rep

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name BIBF-1120,Vargatef Novel drug target Established target

Publications: Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Interaction Types & Directionality: agonist (activating)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor agonist Direct Interaction yes Trial Name becaplermin,Regranex

Publications: Papanas et al., 2008, Becaplermin gel in the treatment of diabetic neuropathic foot ulcers., Clin Interv Aging

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Direct Interaction yes Specific Action of the Ligand Inhibition

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Direct Interaction yes Specific Action of the Ligand Inhibition

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Direct Interaction yes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor Direct Interaction yes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor Direct Interaction yes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Details of the Assay for Interaction Measuring inhibition of kinase activity in a biochemical assay. Specific Action of the Ligand Inhibition Endogenous Drug? False

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name masitinib, AB1010 Novel drug target Established target Direct Interaction yes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Direct Interaction yes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name telatinib Notes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Novel drug target Established target Trial Name motesanib diphosphate, AMG 706

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Specific Action of the Ligand Inhibition

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name dovitinib, TKI-258, CHIR-258 Novel drug target Established target Specific Action of the Ligand Inhibition

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor Direct Interaction? False

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Platelet-derived growth factor receptor inhibitor Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Publications:

Sonpavde et al., 2007, Pazopanib: a novel multitargeted tyrosine kinase inhibitor., Curr Oncol Rep

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name BIBF-1120,Vargatef

Novel drug target Established target

Publications:

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor agonist

Direct Interaction yes

Trial Name becaplermin,Regranex

Publications:

Papanas et al., 2008, Becaplermin gel in the treatment of diabetic neuropathic foot ulcers., Clin Interv Aging

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction Measuring inhibition of kinase activity in a biochemical assay.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name masitinib, AB1010

Novel drug target Established target

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name telatinib

Notes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name motesanib diphosphate, AMG 706

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name dovitinib, TKI-258, CHIR-258

Novel drug target Established target

Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Notes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor beta inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Platelet-derived growth factor receptor inhibitor

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True